MedicarePart B

What Does Medicare Part B Cover?

Medicare Part B is commonly referred to as the Medicare medical benefit and covers a wide range of health care services. Medicare Part B covers physician office visits, outpatient care, ambulance services and medical equipment like a wheelchair or walker.

When it comes to medicines, Part B covers medications administered by a physician, like injected or infused chemotherapy medications. These medicines represent some very significant medical advances, including breakthroughs in cancer, rheumatoid arthritis and autoimmune conditions. Patients may receive these medicines across a number of different care settings. Approximately 600 Part B drugs are administered in different locations like hospital outpatient departments, physician offices, patients' homes and dialysis centers.

Learn more about Part B on the Catalyst Blog.

From The Blog

4 things you need to know about the administration's latest Part B proposal

Medicines Are Not a Key Driver of Medicare Part B Costs

Medicare pays a market-based rate for Part B medicines. Average Sales Price (ASP) is a market-based price that reflects the weighted average of all manufacturer sales prices and includes all rebates and discounts that are privately negotiated between manufacturers and purchasers (with the exception of Medicaid and certain federal discounts and rebates). This methodology allows the government to benefit from discounts negotiated on physician-administered drugs in the commercial market.  

Spending on Part B medicines represents a small and stable share of overall Part B spending at only 8 percent. Recent research found the volume-weighted average sales price for Part B drugs has remained steady year over year, suggesting that prices for prescription medicines and biologicals are not a key driver of program costs. This is in part because Medicare Part B benefits from brand and generic competition, as well as negotiation by commercial payers.

Related Resources

Blog Post

Medicare Monday: Stakeholders raise concern with MedPAC’s proposed changes to drug purchasing program

Blog Post

Medicare Monday: What they are saying about MedPAC’s Part B recommendations

Blog Post

Medicare Monday: A guide to MedPAC’s Part B vote this week

VIEW MORE RESOURCES

Blog Post

Medicare Monday: Billing code basics for biologics in Part B

Blog Post

Medicare Monday: A closer look at Part B spending

Blog Post

Medicare Monday: How Medicare helps beneficiaries access needed medicines

Blog Post

Medicare Monday: A closer look at Medicare Part B

Blog Post

Medicare Monday: New research finds trends in Average Sales Price of Part B drugs remains stable

Blog Post

Medicare Monday: Why Average Sales Price works

Blog Post

Medicare Monday: What is ASP?

Blog Post

Medicare Monday: New research finds drugs not a key driver of Medicare Part B costs

Blog Post

Medicare Monday: How existing CMMI models affect Medicare Part B

Blog Post

Medicare Monday: Part B proposal lacks essential patient protections

Blog Post

New Report: Part B proposal is more aggressive than previous efforts

Blog Post

Medicare Monday: Concerns still abound about Part B proposal

Blog Post

Medicare Monday: Part B and biosimilars, part 2

Blog Post

Medicare Monday: Medicare Part B and biosimilars

Proposed Changes to Part B Put Patients at Risk

There have been a number of proposals to alter the Part B program that would put patients at risk. In 2018, the Department of Health and Human Services (HHS) released an Advance Notice of Proposed Rulemaking, referred to as the International Pricing Index Model, that suggests using the Center for Medicare & Medicaid Innovation (CMMI) to test a mandatory demonstration that would set U.S. prices for medicines covered under Part B based on prices set by 14 foreign governments. The countries that would be referenced in the model use a range of arbitrary techniques to artificially lower prices below market rates, often resulting in severe access restrictions for patients. For example, patients living in the countries referenced by HHS have, on average, access to only 55 percent of new cancer medicines, compared to access to 95 percent in the United States.

In the midst of conversations about changing Part B, it is important to take a step back and reflect on areas where Medicare has gotten it right and the Average Sales Price system is a prime example. It is also important to recognize that changes to Part B could lead to serious, unintended health consequences for Medicare beneficiaries.

VIEW MORE RESOURCES

Blog Post

New Report: Part B proposal is more aggressive than previous efforts

Blog Post

Medicare Monday: Part B proposal lacks essential patient protections

Blog Post

Medicare Monday: 3 things to know about the government’s Medicare payment change

Blog Post

Medicare Monday: Provider consolidation drives up costs for patients and government

Blog Post

340B Spotlight: 340B hospitals account for majority of Part B reimbursements

Blog Post

Medicare Monday: What they’re saying about the CMS proposed Part B payment model

Blog Post

New Research: Access and quality implications of CMS proposed Part B model

Blog Post

Medicare Monday: 3 things to know about Medicare Part B

Blog Post

Medicare Monday: Resources for understanding Medicare Part B and D

Blog Post

Medicare Monday: What does Medicare Part B Cover?

www.medicaments-24.net

https://medicaments-24.com

Augmenter le potentiel